Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer-Reference-Cited by-同舟云学术

Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer

Published:2022-03-25 Issue:7 Volume:65 Page:5675-5689
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Chang Wonsuk¹^ORCID,Altman Michael D.²,Lesburg Charles A.²^ORCID,Perera Samanthi A.²,Piesvaux Jennifer A.²,Schroeder Gottfried K.²,Wyss Daniel F.¹,Cemerski Saso²,Chen Yiping²,DiNunzio Edward¹,Haidle Andrew M.²^ORCID,Ho Thu³,Kariv Ilona²,Knemeyer Ian²,Kopinja Johnny E.²,Lacey Brian M.²,Laskey Jason²,Lim Jongwon²^ORCID,Long Brian J.²,Ma Yanhong²,Maddess Matthew L.²^ORCID,Pan Bo-Sheng²,Presland Jeremy P.²,Spooner Edward²,Steinhuebel Dietrich²,Truong Quang¹,Zhang Zhibo⁴,Fu Jianmin⁴,Addona George H.²,Northrup Alan B.²,Parmee Emma¹,Tata James R.¹,Bennett David Jonathan²,Cumming Jared N.²,Siu Tony²^ORCID,Trotter B. Wesley²

Affiliation:

1. Merck & Co., Inc., Kenilworth, New Jersey 07033, United States

2. Merck & Co., Inc., Boston, Massachusetts 02115, United States

3. Merck & Co., Inc., West Point, Pennsylvania 19486, United States

4. Pharmaron Beijing Co. Ltd., Beijing 100176, P. R. China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c02197

Reference25 articles.